Printer Friendly

FDA APPROVES DISCHARGE FOR PATIENTS WITH THERMO CARDIOSYSTEMS' ELECTRIC HEART-ASSIST DEVICE

 WOBURN, Mass., April 7 /PRNewswire/ -- Thermo Cardiosystems Inc. (AMEX: TCA) announced that the U.S. Food and Drug Administration (FDA) has granted approval for patients with the company's battery-powered electric left ventricular-assist device (LVAD) to be discharged from the Texas Heart Institute at St. Luke's Episcopal Hospital in Houston, provided they meet certain conditions. Thermo Cardiosystems will request permission from the FDA to extend this approval to all of the clinical sites using its HeartMate(R) electric LVAD.
 "This is one of the most significant events in our company's history," said Victor L. Poirier, president of Thermo Cardiosystems. "With their physician's consent, these patients will be able to lead normal lives at home while they wait for a donor heart. This should greatly reduce hospital costs and improve the quality of life for these patients."
 In September 1992, the FDA approved day-trips away from the hospital
for patients whose hearts are being supported byP\Pi Vo !-cg
Jj&Hjk Ualifying patients will be allowed to leave the hospital for up to


several days at a time and, subsequently, be discharged from the hospital to live at home while they await transplantation.
 There are currently three transplant centers in the U.S. with FDA approval to implant the electric LVAD. To date, eight implants of the system have been performed. Powered by a small battery pack that can be worn in a lightweight shoulder holster, the electric LVAD is designed to allow a patient awaiting heart transplantation to move about freely and resume many daily activities.
 An air-driven version of Thermo Cardiosystems' HeartMate LVAD has been used in more than 110 patients under a separate clinical investigation. The company is currently seeking FDA approval for commercial distribution of the air-driven system.
 Thermo Cardiosystems Inc. is a leader in research and development of implantable ventricular-assist devices. These devices are designed to perform substantially all or part of the pumping function of the left ventricle of the natural heart for patients suffering from cardiovascular disease. The company's devices are currently intended for investigational use only. Thermo Cardiosystems is a public subsidiary of Thermedics Inc. and Thermo Electron Corporation.
 -0- 4/7/93
 /CONTACT: John Hatsopoulos of Thermo Electron, 617-622-1111/
 (TMO TCA)


CO: Thermo Electron Corporation; Thermo Cardiosystems Inc. ST: Massachusetts IN: MTC SU:

CH -- NE006 -- 3707 04/07/93 10:13 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1993
Words:389
Previous Article:EDUCATION ALTERNATIVES ANNOUNCES WITHDRAWAL OF PROPOSAL
Next Article:AMVETS/TOYOTA U.S.A. SAFE DRIVING CHALLENGE OFFERS SCHOLARSHIPS TO NEW ENGLAND'S TOP TEEN DRIVERS
Topics:


Related Articles
THERMO CARDIOSYSTEMS' HEART PUMP USED IN ITALY FOR FIRST TIME
PATIENTS ON THERMO CARDIOSYSTEMS ELECTRIC HEART PUMP GET OK FROM FDA TO LEAVE THE HOSPITAL
MEDICAL HISTORY TO BE MADE AS FIRST PATIENT WITH HEART PUMP RETURNS HOME FROM HOSPITAL
HEARTMATE PATIENT LEAVES THE HOSPITAL
THERMO CARDIOSYSTEMS HEART-ASSIST DEVICE TO UNDERGO FDA PANEL REVIEW
FDA PANEL RECOMMENDS COMMERCIAL APPROVAL FOR THERMO CARDIOSYSTEMS' HEARTMATE LVAD
THERMO CARDIOSYSTEMS' ELECTRIC HEART PUMP APPROVED AS AN ALTERNATIVE TO TRANSPLANT IN SWEDEN
PATIENT CELEBRATES ONE-YEAR ANNIVERSARY ON ELECTRIC HEART PUMP
DOCTORS AT COLUMBIA-PRESBYTERIAN IMPLANT THERMO CARDIOSYSTEMS' HEARTMATE DEVICE TO SAVE PATIENT WHO WAS INELIGIBLE FOR TRANSPLANT
Thermo Cardiosystems Receives Approval to Expand Rematch Study

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters